“At the same time that Massachusetts’ residents are starting to receive COVID-19 vaccines, one of which was developed by a Massachusetts’ headquartered company, Governor Baker is for the third time filing an old proposal to penalize drug manufacturers that successfully bring new therapies to market. This policy is unnecessary and ignores the numerous, existing tools the Massachusetts state government has to reduce prescription drug spending.
“MassBio urges the House and Senate to again reject this measure and focus instead on public policies that directly save consumers money at the pharmacy counter, while encouraging the continued success of our world-leading life sciences cluster.”
– Zach Stanley, Executive Vice President, MassBio